重新认识降纤治疗在动静脉缺血性卒中防治中的地位  

Re-recognition of defibrinogen therapy in prevention and management of artery-venous ischemic stroke

作　　者：谷亚钦 段建钢[1,2] 胡舒缘 吉训明[2] GU Yaqin;DUAN Jiangang;HU Shuyuan;JI Xunming(Department of Emergency,Xuanwu Hospital,Capital Medical University,Beijing 100053,P.R.China;Department of Neurology,Xuanwu Hospital,Capital Medical University,Beijing 100053,P.R.China)

机构地区：[1]首都医科大学宣武医院急诊科,北京100053 [2]首都医科大学宣武医院神经内科,北京100053

出　　处：《华西医学》2022年第6期806-812,共7页West China Medical Journal

基　　金：北京市自然科学基金(7182064)。

摘　　要：作为血管性疾病和炎症性疾病的危险因子,纤维蛋白原越来越受到重视,高纤维蛋白原血症与动静脉缺血性卒中(急性缺血性卒中、短暂性脑缺血发作和颅内静脉血栓)的发生、发展及不良预后相关。因此,纤维蛋白原可能是动静脉缺血性卒中防治过程中一个非常有潜力的治疗靶点,但是关于动静脉缺血性卒中的降纤治疗一直存在争议。因此,该文详细介绍了单独降纤、联合抗血小板或联合抗凝在动静脉缺血性卒中防治中的有效性及安全性,旨在重新认识降纤治疗在动静脉缺血性卒中防治中的地位。As a risk factor for vascular diseases and inflammatory diseases,fibrinogen has received more and more attention.Hyperfibrinogenemia is associated with the occurrence,development,and poor outcome of artery-venous ischemic stroke(acute ischemic stroke,transient ischemic attack and cerebral venous thrombosis).Therefore,fibrinogen may be a potential therapeutic target for the prevention and management of artery-venous ischemic stroke.However,there has been controversy regarding the defibrinogen therapy in artery-venous ischemic stroke.Therefore,this paper introduces the efficacy and safety of defibrinogen therapy alone,combined with antiplatelet or combined with anticoagulant in prevention and management of artery-venous ischemic stroke in detail,in order to re-understand the role of defibrinogen therapy in the prevention and management of artery-venous ischemic stroke.

关 键 词：纤维蛋白原 急性缺血性卒中 短暂性脑缺血发作 静脉窦血栓形成 降纤治疗 

分 类 号：R743.3[医药卫生—神经病学与精神病学]